Gilead rises 4.0% after stronger-than-expected quarterly results and raised sales outlook

What happened

Gilead (GILD) rose 4.0% on October 29, 2026, after it beat third-quarter earnings estimates and raised its full-year product sales outlook because of unusually strong base business sales. The company said the quarter produced the strongest year-over-year base business sales growth in over a decade, led by its HIV products, TRODELVY and Livdelzi. Management described the quarter as exceptional and highlighted the breadth and durability of the business on the earnings call, according to Business Wire and Benzinga. The stock opened 2.3% above the previous close and traded with volume 1.4 times its 20-day average.

How big was the move

The stock rose 4.0% on the session and rose 5.4% over the last five sessions, while the S&P 500 fell 0.3% on the day and rose 0.7% over five sessions. The healthcare sector median rose 0.5% on the day, leaving the stock 3.5 percentage points better than the sector median. The session’s move equaled 2.5 times a typical daily move for this stock and matched the size of 16 prior five-year sessions that gained at least 4.0%. Historically, twenty trading days later the median result after such sessions was a decline of 0.8%, with 7 of 16 higher.

The technical picture

The stock traded 8.1% above its 20-day average, 10.2% above its 50-day average and 18.6% above its 200-day average, and it sat at or near its 52-week high. The 50-day average is above the 200-day average, a sign of an established uptrend, and the stock had been above the 200-day average for 59 consecutive trading days. Its Relative Strength Index (14 days) was 70, in a neutral range, and volatility was 25% annualized over 60 days, which ranks higher than 60% of its own readings over five years.

One-month performance showed the stock had risen 11.1%, three-month performance was up 27.2%, and the one-year change was a rise of 40.5%, leaving it 28.5 percentage points ahead of the S&P 500 over the same period. Those gains underpinned momentum scores that place Gilead among stronger performers in its sector, while a beta of 0.34 indicates it tends to move less than the broader market.

Fundamentals and valuation

For the four quarters through September 30, 2026, Gilead reported revenue of $30.99 billion, which grew 6.5% from a year earlier and compared with growth of 5.5% one quarter earlier. Diluted earnings per share for that period was $-3.16, with EPS growth from a year earlier listed as fell 149.0%. Gross margin was 58.5% versus 78.7% a year earlier, and operating margin was 4.4% versus 36.1% a year earlier.

Free-cash-flow margin was 46.1% and return on invested capital was 3.7%. The company’s free-cash-flow yield was 7.4% and share count over one year decreased by 0.2%. Those figures point to a business generating strong cash relative to sales even as accounting earnings and margins reflect recent charges or one-time items that compressed profitability.

PromtFinance scores rank Gilead’s Quality at 81 (Strong) and Stability at 97 (Exceptional), while Growth was 41 (Weak) and Revisions 51 (Neutral). The mix suggests solid underlying business traits and stability but more modest near-term growth metrics.

Earnings and analyst expectations

Gilead reported earnings per share of $2.55 on October 29, 2026, against $2.19 expected, 16.4% above estimates. The result marked eleven consecutive quarters beating estimates and an average surprise of 8.1% above estimates over the last four reports. The company scheduled its next quarterly report for February 9, 2027. The typical two-day market reaction after recent reports was the stock rose 0.4%.

Analysts covering the stock have a consensus price target of $156.67, which is 5.4% below the session’s closing price of $165.61, and 67% of 58 analysts rated the stock Buy or Strong Buy. That split reflects some division between momentum driven by recent results and more cautious views on valuation or long-term growth.

What to watch

• Gilead’s raised full-year product sales outlook to $31 billion–$31.3 billion, up from $30.1 billion–$30.4 billion, citing strength in its HIV portfolio (reported by MarketBeat and WSJ).
• Management commentary on the sustainability of base business sales growth and performance of TRODELVY and Livdelzi, as discussed on the earnings call (reported by Business Wire and Benzinga).
• Progress on pipeline updates and any guidance detail ahead of the February 9, 2027, earnings report.